X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (48) 48
humans (44) 44
oncology (40) 40
cell biology (31) 31
female (25) 25
breast neoplasms - drug therapy (21) 21
middle aged (21) 21
adult (19) 19
breast cancer (19) 19
aged (17) 17
cancer (17) 17
breast neoplasms - pathology (16) 16
neoplasms - genetics (16) 16
biochemistry & molecular biology (13) 13
tcga (13) 13
antineoplastic combined chemotherapy protocols - therapeutic use (12) 12
mutation (12) 12
treatment outcome (12) 12
biology (11) 11
disease-free survival (11) 11
gene expression regulation, neoplastic (11) 11
trastuzumab (10) 10
chemotherapy (9) 9
neoplasms - pathology (9) 9
aged, 80 and over (8) 8
cell line, tumor (8) 8
databases, genetic (8) 8
landscape (8) 8
paclitaxel (8) 8
the cancer genome atlas (8) 8
therapy (8) 8
antineoplastic combined chemotherapy protocols - adverse effects (7) 7
breast neoplasms - metabolism (7) 7
breast-cancer (7) 7
dna methylation (7) 7
drug administration schedule (7) 7
kaplan-meier estimate (7) 7
mutations (7) 7
breast neoplasms - mortality (6) 6
double-blind method (6) 6
efficacy (6) 6
expression (6) 6
genomics (6) 6
neoadjuvant therapy (6) 6
open-label (6) 6
pan-cancer (6) 6
safety (6) 6
taxoids - administration & dosage (6) 6
article (5) 5
breast (5) 5
care and treatment (5) 5
clinical trials (5) 5
cyclophosphamide - administration & dosage (5) 5
double-blind (5) 5
fluorouracil - administration & dosage (5) 5
genome (5) 5
genomics - methods (5) 5
neoplasm staging (5) 5
quinazolines - administration & dosage (5) 5
receptor, erbb-2 - metabolism (5) 5
aneuploidy (4) 4
antineoplastic combined chemotherapy protocols - administration & dosage (4) 4
breast neoplasms - chemistry (4) 4
cancer genomics (4) 4
capecitabine (4) 4
chemotherapy, adjuvant (4) 4
combination (4) 4
discovery (4) 4
docetaxel (4) 4
endocrine therapy (4) 4
hematology, oncology and palliative medicine (4) 4
identification (4) 4
machine learning (4) 4
metastasis (4) 4
microsatellite instability (4) 4
neoplasm metastasis (4) 4
neoplasms - classification (4) 4
phase-ii trial (4) 4
plus (4) 4
postmenopausal women (4) 4
postmenopause (4) 4
prognosis (4) 4
quinazolines - adverse effects (4) 4
reveals (4) 4
somatic mutations (4) 4
time factors (4) 4
transcriptome (4) 4
tumors (4) 4
womens health (4) 4
abridged index medicus (3) 3
adjuvant chemotherapy (3) 3
analysis (3) 3
anthracycline (3) 3
antibodies, monoclonal, humanized - administration & dosage (3) 3
antineoplastic agents, hormonal - therapeutic use (3) 3
biomarkers, tumor - analysis (3) 3
breast neoplasms - genetics (3) 3
c-myc (3) 3
cancer therapies (3) 3
class discovery (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 388, Issue 10063, pp. 2997 - 3005
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 375, Issue 9712, pp. 377 - 384
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 917 - 928
Summary Background CT-P6 is a proposed biosimilar to reference trastuzumab. In this study, we aimed to establish equivalence of CT-P6 to reference trastuzumab... 
Hematology, Oncology and Palliative Medicine | NEOADJUVANT TREATMENT | EPIRUBICIN | ONCOLOGY | CONTROLLED SUPERIORITY TRIAL | OPEN-LABEL | PLUS TRASTUZUMAB | CHEMOTHERAPY | BIOSIMILAR MONOCLONAL-ANTIBODIES | PATHOLOGICAL COMPLETE RESPONSE | ADJUVANT TRASTUZUMAB | PACLITAXEL | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Adenocarcinoma - pathology | Febrile Neutropenia - chemically induced | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Breast Neoplasms - chemistry | Fluorouracil - administration & dosage | Mastectomy | Adult | Female | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Adenocarcinoma - chemistry | Biosimilar Pharmaceuticals - therapeutic use | Biosimilar Pharmaceuticals - administration & dosage | Double-Blind Method | Trastuzumab - adverse effects | Trastuzumab - administration & dosage | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Biosimilar Pharmaceuticals - adverse effects | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged | Receptor, ErbB-2 - analysis | Neoplasm Staging | Adenocarcinoma - surgery | Antimitotic agents | Medical colleges | Adjuvant treatment | Clinical trials | Breast cancer | Product development | Comparative analysis | Antineoplastic agents | Cancer | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2009, Volume 27, Issue 33, pp. 5538 - 5546
Purpose Cross-talk between human epidermal growth factor receptors and hormone receptor pathways may cause endocrine resistance in breast cancer. This trial... 
EFFICACY | ONCOLOGY | RANDOMIZED PHASE-II | TAMOXIFEN RESISTANCE | GROWTH | MCF-7 CELLS | COMBINATION | INHIBITOR | EXPRESSION | ESTROGEN-RECEPTOR | PLUS | Triazoles - administration & dosage | Triazoles - adverse effects | Postmenopause - drug effects | Receptors, Estrogen - metabolism | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma - mortality | Receptors, Progesterone - genetics | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Invasiveness - pathology | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma - pathology | Carcinoma - secondary | Carcinoma - drug therapy | Receptors, Estrogen - genetics | Double-Blind Method | Drug Administration Schedule | Risk Assessment | Biomarkers, Tumor - analysis | Antineoplastic Agents, Hormonal - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Breast Neoplasms - pathology | Quinazolines - adverse effects | Survival Analysis | Breast Neoplasms - mortality | Aged | Biomarkers, Tumor - genetics | Carcinoma - metabolism | Neoplasm Staging | Nitriles - adverse effects | Index Medicus | Carcinoma | Quinazolines | Breast Neoplasms | Life Sciences | Immunology | Triazoles | Postmenopause | Nitriles | Antineoplastic Agents, Hormonal | Tumor Markers, Biological | Receptors, Estrogen | Neoplasm Invasiveness | Antineoplastic Combined Chemotherapy Protocols | Receptor, erbB-2 | Receptors, Progesterone | Kaplan-Meiers Estimate
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2009, Volume 27, Issue 16, pp. 2630 - 2637
Purpose Cross-talk between the estrogen receptor (ER) and the phosphoinositide-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathways is a mechanism... 
INHIBITOR RAD001 EVEROLIMUS | MAMMALIAN TARGET | ADVANCED SOLID TUMORS | ONCOLOGY | TAMOXIFEN | DOUBLE-BLIND | ENDOCRINE THERAPY | AKT | POSTMENOPAUSAL WOMEN | PROGNOSTIC VALUE | MTOR | Cyclin D1 - metabolism | Palpation | Triazoles - administration & dosage | Phosphorylation | Receptors, Estrogen - metabolism | Ribosomal Protein S6 Kinases - metabolism | United States | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Ki-67 Antigen - metabolism | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism | Nitriles - administration & dosage | Time Factors | Aged, 80 and over | Biomarkers, Tumor - metabolism | Postmenopause | Adult | Female | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Everolimus | Aromatase Inhibitors - administration & dosage | Sirolimus - analogs & derivatives | Double-Blind Method | Europe | Treatment Outcome | Breast Neoplasms - drug therapy | Antibiotics, Antineoplastic - administration & dosage | Gene Expression Regulation, Enzymologic | Phosphatidylinositol 3-Kinases - genetics | Sirolimus - administration & dosage | Breast Neoplasms - genetics | Class I Phosphatidylinositol 3-Kinases | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Biopsy | Breast Neoplasms - pathology | Aged | Cell Proliferation - drug effects | Mutation | Index Medicus
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 05/2016, Volume 34, Issue 15, pp. e12535 - e12535
Conference Proceeding
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 05/2016, Volume 34, Issue 15, pp. e12579 - e12579
Conference Proceeding
JAMA, ISSN 0098-7484, 01/2017, Volume 317, Issue 1, pp. 37 - 47
IMPORTANCE: Treatment with the anti-ERBB2 humanized monoclonal antibody trastuzumab and chemotherapy significantly improves outcome in patients with ERBB2... 
ADJUVANT CHEMOTHERAPY | MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | THERAPY | DOCETAXEL | PLUS | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - therapeutic use | Taxoids - therapeutic use | Breast Neoplasms - chemistry | Time Factors | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Antineoplastic Agents, Phytogenic - therapeutic use | Taxoids - adverse effects | Antineoplastic Agents, Phytogenic - adverse effects | Biosimilar Pharmaceuticals - therapeutic use | Trastuzumab - therapeutic use | Double-Blind Method | Antineoplastic Agents - immunology | Paclitaxel - adverse effects | Trastuzumab - adverse effects | Breast Neoplasms - drug therapy | Paclitaxel - therapeutic use | Remission Induction | Disease Progression | Biosimilar Pharmaceuticals - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | Survival Analysis | Breast Neoplasms - mortality | Aged | Receptor, ErbB-2 | Therapeutic Equipoise | Trastuzumab - immunology | Outcome and process assessment (Health Care) | Care and treatment | Breast cancer | Health aspects | Analysis | Young women | Patient safety | Oncology | Biological products | Biomedical research | Womens health | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 14, pp. 1564 - 1573
Journal Article
by Thorsson, Vesteinn and Thorsson, Vésteinn and Gibbs, Richard A and Gibbs, David L and Brown, Scott D and Wolf, Gregory and Wolf, Denise and Bortone, Dante S and Ou Yang, Tai-Hsien and Porta-Pardo, Eduard and Gao, Galen F and Gao, Jianjiong and Plaisier, Christopher L and Eddy, James A and Ziv, Elad and Culhane, Aedin C and Paull, Evan O and Sivakumar, I.K. Ashok and Gentles, Andrew J and Malhotra, Raunaq and Farshidfar, Farshad and Colaprico, Antonio and Parker, Joel S and Mose, Lisle E and Vo, Nam Sy and Liu, Wenbin and Liu, Jianfang and Liu, Jia and Liu, Yuexin and Liu, Xiuping and Rader, Janet and Dhankani, Varsha and Reynolds, Sheila and Reynolds, Sheila M and Bowlby, Reanne and Califano, Andrea and Cherniack, Andrew D and Anastassiou, Dimitris and Bedognetti, Davide and Mokrab, Younes and Newman, Aaron M and Rao, Arvind and Chen, Amy and Chen, Chu and Chen, Ken and Krasnitz, Alexander and Hu, Jianhong and Hu, Hai and Malta, Tathiane M and Noushmehr, Houtan and Pedamallu, Chandra Sekhar and Bullman, Susan and Ojesina, Akinyemi I and Lamb, Andrew and Zhou, Wanding and Shen, Hui and Choueiri, Toni K and Weinstein, John N and Guinney, Justin and Saltz, Joel and Holt, Robert and Holt, Robert A and Rabkin, Charles S and Caesar-Johnson, Samantha J and Demchok, John A and Felau, Ina and Kasapi, Melpomeni and Ferguson, Martin L and Hutter, Carolyn M and Sofia, Heidi J and Tarnuzzer, Roy and Wang, Jioajiao and Wang, Min and Wang, Linghua and Wang, Zhining and Wang, Timothy and Wang, Jing and Yang, Ju Dong and Yang, Hannah and Yang, Liming and Yang, Ian and Zenklusen, Jean C and Zhang, Jiashan (Julia) and Zhang, Jiexin and Zhang, Lizhi and Zhang, Wei and Zhang, Hongzheng and Zhang, Hailei and Zhang, Hongxin and Chudamani, Sudha and Lolla, Laxmi and Naresh, Rashi and Pihl, Todd and Sun, Yichao and Sun, Qiang and Wan, Yunhu and Wu, Ye and Cho, Juok and DeFreitas, Timothy and Frazer, Scott and ... and Canc Genome Atlas Res Network and Cancer Genome Atlas Research Network
Immunity, ISSN 1074-7613, 04/2018, Volume 48, Issue 4, pp. 812 - 830.e14
We performed an extensive immunogenomic analysis of more than 10,000 tumors comprising 33 diverse cancer types by utilizing data compiled by TCGA. Across... 
tumor immunology | immunotherapy | cancer genomics | integrative network analysis | immuno-oncology | tumor microenvironment | immune subtypes | immunomodulatory | GENOMIC ANALYSES | INFORMATION | T-CELL-RECEPTOR | REGULATORY NETWORK | CLASSIFICATION | IMMUNOLOGY | SEQUENCING DATA | SOMATIC MUTATIONS | COMPREHENSIVE ANALYSIS | PREDICTION | REVEALS | Transforming Growth Factor beta - immunology | Prognosis | Humans | Middle Aged | Th1-Th2 Balance - physiology | Male | Neoplasms - classification | Wound Healing - immunology | Young Adult | Transforming Growth Factor beta - genetics | Neoplasms - genetics | Neoplasms - immunology | Interferon-gamma - immunology | Adolescent | Aged, 80 and over | Adult | Female | Aged | Interferon-gamma - genetics | Wound Healing - genetics | Genomics - methods | Child | Macrophages - immunology | Cell proliferation | Cluster analysis | Transcription | Copy number | p53 Protein | Lung cancer | Genomics | Aneuploidy | Lymphocytes T | Genomes | Cell interactions | Macrophages | Immunotherapy | DNA methylation | Deoxyribonucleic acid--DNA | Immune system | Medical research | Wound healing | Immunomodulation | MiRNA | Stockholders | Inflammation | T cell receptors | Communications networks | Gene expression | White blood cells | Inventors | Medical prognosis | γ-Interferon | Mutation | Cancer | Tumors | Index Medicus | Immune Subtypes | Integrative Network Analysis | Cancer Genomics | Immuno-oncology | Tumor immunology
Journal Article